362 related articles for article (PubMed ID: 10759015)
21. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.
Matsui H; Sugimoto M; Tsuji S; Shima M; Giddings J; Yoshioka A
J Pediatr Hematol Oncol; 1999; 21(1):74-6. PubMed ID: 10029819
[TBL] [Abstract][Full Text] [Related]
22. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group.
Lusher JM; Salzman PM
Semin Hematol; 1990 Apr; 27(2 Suppl 2):1-7. PubMed ID: 1965615
[TBL] [Abstract][Full Text] [Related]
23. Specific inactivation of viruses which can potentially contaminate blood products.
Horowitz B
Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
[TBL] [Abstract][Full Text] [Related]
24. Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients.
Philipp CS;
Haemophilia; 2001 Mar; 7(2):146-53. PubMed ID: 11260273
[TBL] [Abstract][Full Text] [Related]
25. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
Heimburger N; Karges HE; Weidmann E
Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
[TBL] [Abstract][Full Text] [Related]
26. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G
Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615
[TBL] [Abstract][Full Text] [Related]
27. Assessment of needs for plasma for fractionation in Europe.
Burckhardt JJ
Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061
[TBL] [Abstract][Full Text] [Related]
28. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
29. Continuous-flow UVC irradiation: a new, effective, protein activity-preserving system for inactivating bacteria and viruses, including erythrovirus B19.
Caillet-Fauquet P; Di Giambattista M; Draps ML; Sandras F; Branckaert T; de Launoit Y; Laub R
J Virol Methods; 2004 Jun; 118(2):131-9. PubMed ID: 15081608
[TBL] [Abstract][Full Text] [Related]
30. "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate.
Arrighi S; Rossi R; Borri MG; Lesnikov V; Lesnikova M; Franco E; Divizia M; De Santis ME; Bucci E
Thromb Haemost; 1995 Sep; 74(3):868-73. PubMed ID: 8571312
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of wet pasteurization of a factor VIII concentrate produced by controlled-pore silica adsorption.
Hiemstra H; Nieuweboer CE; Idoe MA; Claassen JE; Vos AH; Tersmette M; Strengers PF; Over J; Mauser-Bunschoten EP; Heijboer H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):557-63. PubMed ID: 1714860
[TBL] [Abstract][Full Text] [Related]
33. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
34. [HIV safety of commercially produced human plasma proteins].
Hilfenhaus J
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():84-8. PubMed ID: 8000262
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
36. Reducing the risk of infection from plasma products: specific preventative strategies.
Burnouf T; Radosevich M
Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
[TBL] [Abstract][Full Text] [Related]
37. Current safety of clotting factor concentrates.
Epstein JS; Fricke WA
Arch Pathol Lab Med; 1990 Mar; 114(3):335-40. PubMed ID: 2407224
[TBL] [Abstract][Full Text] [Related]
38. Clinical studies with treated clotting factor concentrates.
Colombo M; Mannucci PM
Dev Biol Stand; 1987; 67():333-6. PubMed ID: 3038639
[TBL] [Abstract][Full Text] [Related]
39. Human anti-mouse immunoglobulins in sera of patients treated chronically with monoclonal antibody-purified factor VIII.
Haimovich J; Davis HM; Schreiber AB
Semin Hematol; 1990 Apr; 27(2 Suppl 2):11-5. PubMed ID: 2128852
[TBL] [Abstract][Full Text] [Related]
40. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
Stadler M; Gruber G; Kannicht C; Biesert L; Radomski KU; Suhartono H; Pock K; Neisser-Svae A; Weinberger J; Römisch J; Svae TE
Biologicals; 2006 Dec; 34(4):281-8. PubMed ID: 16500114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
